Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2019 | Hospital exemption: enabling patients’ access to advanced therapies in the EU

Valentín Ortiz-Maldonado • 10 Apr 2019
EBMT 2019
General

Advancements in biomedical sciences are leading to novel treatment options for the treatment of hematological malignancies. Despite the promising development activity in the Advanced Therapy Medicinal Product (ATMP) field, the number of ATMPs currently available in the European market remains limited due to high regulatory demands. Valentín Ortiz-Maldonado, MD, of Hospital Clinic of Barcelona, Barcelona, Spain, mentions that applying a hospital exemption can significantly accelerate cancer patients’ access to advanced therapies, and ultimately increase their survival chances. This video was recorded at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Valentín Ortiz-Maldonado

1:26
The major benefits of producing academic CAR T-cells
Valentín Ortiz-Maldonado • 10 Dec 2023
3:03
The impact of salvage and bridging therapy on CAR T-cell therapy outcomes in B-ALL: an ITT analysis
Valentín Ortiz-Maldonado • 10 Dec 2023
2:58
Var-cel shows promise for the treatment of CLL and Richter's transformation
Valentín Ortiz-Maldonado • 10 Dec 2023
2:25
Efficacy of varnimcabtagene autoleucel in patients with R/R BCL with no indication for CAR-T therapy
Valentín Ortiz-Maldonado • 8 Jun 2023

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals